Trials / Active Not Recruiting
Active Not RecruitingNCT04454476
Reversal of Preneoplastic Metaplasia in the Stomach With MEK Inhibitor
Reversal of Preneoplastic Metaplasia in the Stomach With MEK Inhibitor Treatment
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- Sponsor
- Vanderbilt-Ingram Cancer Center · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This is a study of the safety and effectiveness of Trametinib treatment in patients who have received successful endoscopic submucosal resection of a Stage I gastric cancer.
Detailed description
Objectives: * To evaluate the efficacy of Trametinib in reversing metaplasia in participants with Stage 1 gastric cancer * To evaluate the safety of Trametinibin in Stage I gastric cancer patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Trametinib treatment | 1 mg taken by mouth once a day for 14 days |
| PROCEDURE | Endoscopy | A tiny camera on the end of a long, flexible tube will be used to examine the stomach and take biopsies. |
Timeline
- Start date
- 2022-11-09
- Primary completion
- 2024-12-01
- Completion
- 2025-12-01
- First posted
- 2020-07-01
- Last updated
- 2024-07-31
Locations
3 sites across 1 country: Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04454476. Inclusion in this directory is not an endorsement.